Cellect Biotechnology (APOP) Downgraded to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Cellect Biotechnology (NASDAQ:APOP) from a buy rating to a hold rating in a report issued on Wednesday.

According to Zacks, “Cellect Biotechnology Ltd. offers biomedical services. It provides stem cell transplantation, disease management, regenerative medicine, clinical research and other services. Cellect Biotechnology Ltd. is based in TEL AVIV, Israel. “

How to Become a New Pot Stock Millionaire

Separately, HC Wainwright set a $14.00 price objective on Cellect Biotechnology and gave the company a buy rating in a research note on Friday, January 5th.

Shares of APOP opened at $6.54 on Wednesday. Cellect Biotechnology has a one year low of $6.12 and a one year high of $13.50.

Cellect Biotechnology (NASDAQ:APOP) last issued its quarterly earnings results on Monday, March 19th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. research analysts predict that Cellect Biotechnology will post -1.3 EPS for the current fiscal year.

An institutional investor recently bought a new position in Cellect Biotechnology stock. Susquehanna International Group LLP acquired a new stake in shares of Cellect Biotechnology (NASDAQ:APOP) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 12,764 shares of the company’s stock, valued at approximately $101,000. Susquehanna International Group LLP owned approximately 0.23% of Cellect Biotechnology as of its most recent SEC filing. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/cellect-biotechnology-apop-downgraded-to-hold-at-zacks-investment-research.html.

Cellect Biotechnology Company Profile

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Get a free copy of the Zacks research report on Cellect Biotechnology (APOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply